JP7479293B2 - プテリジノン化合物およびその使用 - Google Patents
プテリジノン化合物およびその使用 Download PDFInfo
- Publication number
- JP7479293B2 JP7479293B2 JP2020559365A JP2020559365A JP7479293B2 JP 7479293 B2 JP7479293 B2 JP 7479293B2 JP 2020559365 A JP2020559365 A JP 2020559365A JP 2020559365 A JP2020559365 A JP 2020559365A JP 7479293 B2 JP7479293 B2 JP 7479293B2
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- compound
- acceptable salt
- ceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098522A JP2023116712A (ja) | 2018-04-24 | 2023-06-15 | プテリジノン化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661744P | 2018-04-24 | 2018-04-24 | |
| US62/661,744 | 2018-04-24 | ||
| PCT/US2019/028604 WO2019209757A1 (en) | 2018-04-24 | 2019-04-23 | Pteridinone compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098522A Division JP2023116712A (ja) | 2018-04-24 | 2023-06-15 | プテリジノン化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522237A JP2021522237A (ja) | 2021-08-30 |
| JP2021522237A5 JP2021522237A5 (cg-RX-API-DMAC7.html) | 2022-04-22 |
| JP7479293B2 true JP7479293B2 (ja) | 2024-05-08 |
Family
ID=66655428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559365A Active JP7479293B2 (ja) | 2018-04-24 | 2019-04-23 | プテリジノン化合物およびその使用 |
| JP2023098522A Pending JP2023116712A (ja) | 2018-04-24 | 2023-06-15 | プテリジノン化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098522A Pending JP2023116712A (ja) | 2018-04-24 | 2023-06-15 | プテリジノン化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11059826B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3784669B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7479293B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112218865B (cg-RX-API-DMAC7.html) |
| AR (1) | AR114828A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019257651B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3097774A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2969982T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278122B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI884914B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019209757A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023116712A (ja) * | 2018-04-24 | 2023-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プテリジノン化合物およびその使用 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| US12617784B2 (en) | 2019-01-29 | 2026-05-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| WO2022023339A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| EP4238974A4 (en) * | 2020-10-28 | 2024-10-23 | Adlai Nortye Biopharma Co., Ltd. | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
| TW202333697A (zh) * | 2022-01-30 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Wnt通路抑制劑化合物 |
| CN114436918B (zh) * | 2022-02-23 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在药物中的应用 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005501904A (ja) | 2001-09-04 | 2005-01-20 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| JP2008503515A (ja) | 2004-06-21 | 2008-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規2−ベンジルアミノジヒドロプテリジノン、それらを製造する方法及び薬剤としてのそれらの使用 |
| JP2008509948A (ja) | 2004-08-14 | 2008-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞増殖を伴う疾患の治療のための複合薬 |
| JP2008510750A (ja) | 2004-08-25 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン誘導体、その製造方法及び薬物としての使用 |
| US20130225593A1 (en) | 2012-02-23 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| WO2015193229A1 (de) | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| JP2016509033A (ja) | 2013-02-21 | 2016-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンi |
| JP2016513116A (ja) | 2013-02-21 | 2016-05-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンii |
| CN105801582A (zh) | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
| JP2017512186A (ja) | 2014-01-31 | 2017-05-18 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジヒドロプテリジノン誘導体およびその使用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| AU2011226830A1 (en) * | 2004-08-14 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007014838A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2986441A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3784669B1 (en) * | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
-
2019
- 2019-04-23 EP EP19726791.7A patent/EP3784669B1/en active Active
- 2019-04-23 JP JP2020559365A patent/JP7479293B2/ja active Active
- 2019-04-23 WO PCT/US2019/028604 patent/WO2019209757A1/en not_active Ceased
- 2019-04-23 AU AU2019257651A patent/AU2019257651B2/en active Active
- 2019-04-23 AR ARP190101061A patent/AR114828A1/es unknown
- 2019-04-23 ES ES19726791T patent/ES2969982T3/es active Active
- 2019-04-23 CN CN201980035546.1A patent/CN112218865B/zh active Active
- 2019-04-23 US US16/391,407 patent/US11059826B2/en active Active
- 2019-04-23 CA CA3097774A patent/CA3097774A1/en active Pending
- 2019-04-23 TW TW108114117A patent/TWI884914B/zh active
- 2019-04-23 IL IL278122A patent/IL278122B2/en unknown
-
2021
- 2021-03-01 US US17/188,132 patent/US11572364B2/en active Active
-
2022
- 2022-12-05 US US18/075,270 patent/US12384790B2/en active Active
-
2023
- 2023-06-15 JP JP2023098522A patent/JP2023116712A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005501904A (ja) | 2001-09-04 | 2005-01-20 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| JP2008503515A (ja) | 2004-06-21 | 2008-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規2−ベンジルアミノジヒドロプテリジノン、それらを製造する方法及び薬剤としてのそれらの使用 |
| JP2008509948A (ja) | 2004-08-14 | 2008-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞増殖を伴う疾患の治療のための複合薬 |
| JP2008510750A (ja) | 2004-08-25 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン誘導体、その製造方法及び薬物としての使用 |
| US20130225593A1 (en) | 2012-02-23 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| JP2016509033A (ja) | 2013-02-21 | 2016-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンi |
| JP2016513116A (ja) | 2013-02-21 | 2016-05-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンii |
| JP2017512186A (ja) | 2014-01-31 | 2017-05-18 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジヒドロプテリジノン誘導体およびその使用 |
| WO2015193229A1 (de) | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| CN105801582A (zh) | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
Non-Patent Citations (2)
| Title |
|---|
| LI QIU; ET AL,DESIGN, SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF NOVEL SUBSTITUTED 2-AMINO-7,8-DIHYDROPTERIDIN-6(5H)-ONE DERIVATIVES,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,PERGAMON,2017年07月29日,VOL:27, NR:17,PAGE(S):3954-3958,http://dx.doi.org/10.1016/j.bmcl.2017.07.076 |
| LUKE W KOBLAN; ET AL,ASSESSMENT OF BROMODOMAIN TARGET ENGAGEMENT BY A SERIES OF BI2536 ANALOGUES WITH MINIATURIZED BET-BRET,CHEMMEDCHEM,ドイツ,2016年12月06日,VOL:11, NR:23,PAGE(S):2575-2581,http://dx.doi.org/10.1002/cmdc.201600502 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023116712A (ja) * | 2018-04-24 | 2023-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プテリジノン化合物およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202010744A (zh) | 2020-03-16 |
| EP3784669A1 (en) | 2021-03-03 |
| CN112218865B (zh) | 2024-03-12 |
| TWI884914B (zh) | 2025-06-01 |
| US20230312587A1 (en) | 2023-10-05 |
| IL278122B1 (en) | 2023-09-01 |
| US12384790B2 (en) | 2025-08-12 |
| US11059826B2 (en) | 2021-07-13 |
| CN112218865A (zh) | 2021-01-12 |
| US20220363685A1 (en) | 2022-11-17 |
| IL278122A (en) | 2020-11-30 |
| AU2019257651A1 (en) | 2020-10-15 |
| WO2019209757A1 (en) | 2019-10-31 |
| AR114828A1 (es) | 2020-10-21 |
| US11572364B2 (en) | 2023-02-07 |
| JP2021522237A (ja) | 2021-08-30 |
| EP3784669B1 (en) | 2023-10-25 |
| ES2969982T3 (es) | 2024-05-23 |
| AU2019257651B2 (en) | 2023-05-25 |
| IL278122B2 (en) | 2024-01-01 |
| CA3097774A1 (en) | 2019-10-31 |
| JP2023116712A (ja) | 2023-08-22 |
| US20190322673A1 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI884914B (zh) | 喋啶酮化合物及其用途 | |
| CN116554168B (zh) | Cxcr4抑制剂及其用途 | |
| KR20230172548A (ko) | Mek 억제제 및 이의 용도 | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| JP2022534425A (ja) | Tead阻害剤およびその使用 | |
| JP2023553866A (ja) | Tead阻害剤、及びその使用 | |
| JP2019518768A (ja) | Cxcr4阻害剤およびその使用 | |
| US20240092779A1 (en) | Usp1 inhibitors and uses thereof | |
| US12459895B2 (en) | MEK inhibitors and uses thereof | |
| EP3846793A1 (en) | Eif4e inhibitors and uses thereof | |
| WO2021263203A1 (en) | Cxcr4 inhibitors and uses thereof | |
| WO2023173057A1 (en) | Mek inhibitors and uses thereof | |
| JP2022538138A (ja) | Cxcr4阻害剤およびその使用 | |
| EA047483B1 (ru) | Ингибиторы tead и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220414 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230315 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230925 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240221 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240411 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240423 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7479293 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |